'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective.
Lewis
James H
JH
Division of Gastroenterology, Georgetown University Medical Center, Washington, District of Columbia 20007, USA. lewisjh@gunet.georgetown.edu
D000410:Alanine Transaminase / Q000097:blood; D000925:Anticoagulants / Q000009:adverse effects; D001384:Azetidines / Q000009:adverse effects; D001596:Benzylamines / Q000009:adverse effects; D001663:Bilirubin / Q000097:blood; D015415:Biomarkers / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000201:enzymology / Q000209:etiology*; D002839:Chromans / Q000009:adverse effects*; D017277:Drug Approval; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D007565:Jaundice / Q000097:blood / Q000201:enzymology / Q000209:etiology; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D017114:Liver Failure, Acute / Q000097:blood / Q000201:enzymology / Q000209:etiology*; D017891:Pharmacoepidemiology / Q000639:trends; D011237:Predictive Value of Tests; D018570:Risk Assessment; D045162:Thiazolidinediones / Q000009:adverse effects*; D000077288:Troglitazone; D014481:United States; D014486:United States Food and Drug Administration
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D015415:Biomarkers; D002839:Chromans; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; C426686:ximelagatran; D000410:Alanine Transaminase; D000077288:Troglitazone; D001663:Bilirubin